概括
由于心血管风险增加,不建议给有重大心血管疾病病史的患者使用febuxostat. 对于这些人来说,应该考虑替代性痛风治疗.
科学领域:
- 药物监督 药物监督 药物监督
- 心血管安全心血管安全
- 痛风治疗方法 痛风治疗方法
背景情况:
- 费布克索斯塔特是一种用于高尿血症的丁氧化酶抑制剂.
- 以前的研究表明,使用febuxostat可能会增加心血管事件.
- 监管机构正在重新评估febuxostat在特定患者群体中的安全性.
研究的目的:
- 提供关于使用febuxostat的最新安全建议.
- 在患有先前心血管疾病的患者中评估与febuxostat相关的心血管风险.
- 为指导医疗保健专业人员管理心血管病史的痛风患者.
主要方法:
- 对营销后监测数据的审查.
- 对临床试验数据的分析,重点关注心血管结果.
- 评估向监管机构提交的安全报告.
主要成果:
- 在有心血管疾病病史的患者中,费布克索斯塔与重大心血管不良事件 (MACE) 的风险增加有关.
- 在这个特定的患者群体中,费布克索斯塔特的益处风险平衡是不利的.
- 持续监测和报告心血管事件至关重要.
结论:
- 在有重大心血管疾病病史的患者中,Febuxostat是禁忌的,或应非常谨慎地使用.
- 对于高心血管风险的患者,应考虑替代性尿酸降低疗法.
- 医疗保健提供者必须在开处方febuxostat之前仔细权衡风险和益处.
相关概念视频
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
575
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
575
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.5K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.5K
Heart Failure Drugs: β-Blockers
382
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
382
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
568
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
568
Cardiovascular Drugs: Classification based on Therapeutic Indications
2.9K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.9K
Heart Failure Drugs: Diuretics
426
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
426


